Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Yue Wang,

Sherlot Juan Song,

Yichong Jiang

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Июнь 27, 2024

In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring progression, predicting development liver-related complications, and treatment response are crucial.The advantage simple fibrosis scores lies in their widespread accessibility through routinely performed blood tests extensive validation different clinical settings.They have shown reasonable accuracy diagnosing advanced good performance excluding majority patients with a low risk complications.Among elevated serum scores, more specific imaging biomarker has proved useful to accurately identify at biomarkers, enhanced is most widely utilized been approved United States as prognostic biomarker.For availability vibration-controlled transient elastography largely improved past years, enabling use stiffness measurement (LSM) accurate assessment significant fibrosis, cirrhosis.Combining LSM other available enhances ability diagnose at-risk steatohepatitis; predict some reaching an comparable that biopsy.Magnetic resonance imaging-based modalities provide quantification though current utilization limited research settings.Expanding future practice depends on factors such cost facility availability.

Язык: Английский

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges DOI Open Access
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill

и другие.

Metabolism, Год журнала: 2024, Номер 154, С. 155835 - 155835

Опубликована: Март 19, 2024

Язык: Английский

Процитировано

80
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease DOI Creative Commons
Zobair M. Younossi,

Markos Kalligeros,

Linda Henry

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 19, 2024

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does prevalence metabolic dysfunction associated steatotic liver disease (MASLD). Currently, 38% all adults 7-14% children adolescents have MASLD. By 2040, MASLD rate for is projected over 55%. Although many with will not develop progressive disease, given vast number patients MASLD, it has now become top indication transplant in United States those hepatocellular carcinoma (HCC) women. However, most common cause mortality among remains death cardiovascular diseases. In addition outcomes (cirrhosis HCC), increased risk developing de-novo T2D, chronic kidney sarcopenia extrahepatic cancers. Furthermore, decreased health related quality life, work productivity, fatigue healthcare resource utilization substantial economic burden. Similar other lifestyle interventions heathy diet physical activity remain cornerstone managing these patients. a T2D drugs are available treat co-morbid Resmetirom only MASH-targeted medication that was recently approved by Federal Drug Administration use stage 2-3 fibrosis. The following review provides an overview epidemiology, its factors demonstrates without further global initiatives, may increase.

Язык: Английский

Процитировано

58
WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography DOI Creative Commons
Giovanna Ferraioli, R. Graham Barr, Annalisa Berzigotti

и другие.

Ultrasound in Medicine & Biology, Год журнала: 2024, Номер 50(8), С. 1071 - 1087

Опубликована: Май 17, 2024

Язык: Английский

Процитировано

36
Metabolic dysfunction-associated steatotic liver disease and its link to cancer DOI

Markos Kalligeros,

Linda Henry, Zobair M. Younossi

и другие.

Metabolism, Год журнала: 2024, Номер 160, С. 156004 - 156004

Опубликована: Авг. 24, 2024

Язык: Английский

Процитировано

22
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050 DOI Creative Commons
Phuc Le, Moosa Tatar, Srinivasan Dasarathy

и другие.

JAMA Network Open, Год журнала: 2025, Номер 8(1), С. e2454707 - e2454707

Опубликована: Янв. 17, 2025

Importance Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common cause of chronic and projected to become leading indication for transplant (LT) in US. Understanding its clinical burden can help identify opportunities prevention treatment. Objective To project MASLD US adults from 2020 2050. Design, Setting, Participants This decision analytical modeling study used an agent-based state transition model that simulates natural history progression among 18 years age or older. Primary data sources inputs were published literature. Exposure Natural MASLD. Main Outcomes Measures Cases MASLD, metabolic steatohepatitis (MASH), fibrosis, hepatocellular carcinoma (HCC), LT, liver-related death. Results The simulated 2 821 624 individuals (mean age. 35.8 years; 50.9% female). predicted a steady increase prevalence 33.7% (86.3 million people) 41.4% (121.9 by MASH would 14.9 (5.8% adults) 23.2 (7.9% number cases clinically significant fibrosis (ie, F≥F2, centrilobular periportal more severe disease) estimated 6.7 11.7 million. By 2046 2050, 22 440 new HCC 6720 LT per year compared with 11 483 1717 2025. Liver-related mortality was 30 500 deaths (1.0% all-cause 95 300 (2.4%) Conclusions Relevance In this study, forecast substantial over next 3 decades absence effective treatments. These results suggest health systems should plan large increases need LT.

Язык: Английский

Процитировано

11
The growing range of complications of diabetes mellitus DOI
Peter Shane Hamblin, Anthony Russell, Stella Talic

и другие.

Trends in Endocrinology and Metabolism, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

2
Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes DOI
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay

и другие.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Год журнала: 2025, Номер 19(3), С. 103209 - 103209

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

2
Surveillance of the liver in type 2 diabetes: important but unfeasible? DOI Creative Commons
S. U. Qadri, Hannele Yki‐Järvinen

Diabetologia, Год журнала: 2024, Номер 67(6), С. 961 - 973

Опубликована: Фев. 9, 2024

Abstract Fatty liver plays a pivotal role in the pathogenesis of metabolic syndrome and type 2 diabetes. According to an updated classification, any individual with steatosis one or more features syndrome, without excess alcohol consumption other known causes steatosis, has dysfunction-associated steatotic disease (MASLD). Up 60–70% all individuals diabetes have MASLD. However, prevalence advanced fibrosis remains uncertain, reported estimates 10–20% relying on imaging tests likely overestimating true prevalence. All stages MASLD impact prognosis but is best predictor all-cause liver-related mortality risk. People face two- threefold increase risk death hepatocellular carcinoma, 1.3% progressing severe over 7.7 years. Because reliable methods for detecting are lacking, mostly incidental finding imaging. Regardless, several medical societies advocate universal screening fibrosis. Proposed pathways involve annual calculation Fibrosis-4 (FIB-4) index, followed by secondary test such as transient elastography (TE) intermediate-to-high-risk individuals. owing unsatisfactory biomarker specificity, these expected channel approximately 40% TE 20% tertiary care, false discovery rate up 80%, raising concerns about feasibility. There thus urgent need develop effective strategies surveying Nonetheless, weight loss through lifestyle changes, pharmacotherapy bariatric surgery cornerstone management, proving highly not only comorbidities also Emerging evidence suggests that biomarkers may serve tools risk-based targeting weight-loss interventions potentially monitoring response therapy. Graphical

Язык: Английский

Процитировано

14
Endpoints in NASH Clinical Trials: Are We Blind in One Eye? DOI Creative Commons
Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani

и другие.

Metabolites, Год журнала: 2024, Номер 14(1), С. 40 - 40

Опубликована: Янв. 8, 2024

This narrative review aims to illustrate the notion that nonalcoholic steatohepatitis (NASH), recently renamed metabolic dysfunction-associated (MASH), is a systemic disorder featuring both adverse hepatic and extrahepatic outcomes. In recent years, several NASH trials have failed identify effective pharmacological treatments and, therefore, lifestyle changes are cornerstone of therapy for NASH. with this context, we analyze epidemiological burden possible pathogenetic factors involved. These include genetic factors, insulin resistance, lipotoxicity, immuno-thrombosis, oxidative stress, reprogramming metabolism, hypoxia, all which eventually culminate in low-grade chronic inflammation increased risk fibrosis progression. The explanations underlying failure also accurately examined. We conclude high heterogeneity NASH, resulting from variable backgrounds, exposure, responses different stresses, susceptibility hepatocyte differences repair-response, calls personalized medicine approaches involving research on noninvasive biomarkers. Future should aim at achieving complete assessment determinants, modifiers, correlates thus adopting more holistic unbiased approach, notably including cardiovascular–kidney–metabolic outcomes, without restricting therapeutic perspectives histological surrogates liver-related outcomes alone.

Язык: Английский

Процитировано

13
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach DOI
Nicholas Chew, Anurag Mehta, Rachel Sze Jen Goh

и другие.

Circulation, Год журнала: 2024, Номер 151(1), С. 98 - 119

Опубликована: Дек. 26, 2024

There is a new awareness of the widespread nature metabolic dysfunction–associated steatotic liver disease (MASLD) and its connection to cardiovascular (CVD). This has catalyzed collaboration between cardiologists, hepatologists, endocrinologists, wider multidisciplinary team address need for earlier identification those with MASLD who are at increased risk CVD. The overlap in pathophysiologic processes parallel prevalence CVD, syndrome, highlight multisystem consequences poor cardiovascular–liver–metabolic health. Metabolic dysfunction associated insulin resistance, together predilection ectopic fat deposition surrounding tissues, elevated endothelial dysfunction, systemic inflammatory response, epicardium. complex pathophysiology can accelerate atherogenic dyslipidemia, atherogenesis, diastolic valvular calcification, cardiac arrhythmias. Despite mounting evidence mechanistic pathways underpinning current recommendations have not clearly focused upon as factor or target intervention We brought diverse range international experts committed promoting health related outcomes across globe. overarching goal this document offer construct clinicians field regards (1) diagnosis screening through use noninvasive serum imaging tests; (2) CVD all individuals regardless established atherosclerotic factors; (3) approach management respect prevention lifestyle, well pharmacologic surgical strategies. To achieve this, modified Delphi method was applied series evidence-based quality standard been identified.

Язык: Английский

Процитировано

11